Bonsignori et al., 2011 - Google Patents
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestorsBonsignori et al., 2011
View PDF- Document ID
- 17073304252344672734
- Author
- Bonsignori M
- Hwang K
- Chen X
- Tsao C
- Morris L
- Gray E
- Marshall D
- Crump J
- Kapiga S
- Sam N
- Sinangil F
- Pancera M
- Yongping Y
- Zhang B
- Zhu J
- Kwong P
- O'Dell S
- Mascola J
- Wu L
- Nabel G
- Phogat S
- Seaman M
- Whitesides J
- Moody M
- Kelsoe G
- Yang X
- Sodroski J
- Shaw G
- Montefiori D
- Kepler T
- Tomaras G
- Alam S
- Liao H
- Haynes B
- Publication year
- Publication venue
- Journal of virology
External Links
Snippet
ABSTRACT V2/V3 conformational epitope antibodies that broadly neutralize HIV-1 (PG9 and PG16) have been recently described. Since an elicitation of previously known broadly neutralizing antibodies has proven elusive, the induction of antibodies with such specificity …
- 241000713772 Human immunodeficiency virus 1 0 title abstract description 39
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bonsignori et al. | Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors | |
| Lynch et al. | The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter | |
| Morris et al. | Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting | |
| Bonsignori et al. | Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family | |
| Huang et al. | Broad and potent neutralization of HIV-1 by a gp41-specific human antibody | |
| Mikell et al. | Characteristics of the earliest cross-neutralizing antibody response to HIV-1 | |
| Shen et al. | In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth | |
| Gorny et al. | Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles | |
| Tomaras et al. | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals | |
| Moody et al. | HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages | |
| Li et al. | Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01 | |
| US20160244510A1 (en) | Human monoclonal antibodies | |
| Gorny et al. | Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals | |
| Hoffenberg et al. | Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes | |
| Krachmarov et al. | Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1 | |
| Gnanakaran et al. | Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies | |
| Kumar et al. | An HIV-1 broadly neutralizing antibody from a clade C-infected pediatric elite neutralizer potently neutralizes the contemporaneous and autologous evolving viruses | |
| Tang et al. | Epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals | |
| Rosenberg et al. | Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques | |
| Chen et al. | A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design | |
| Huber et al. | Very few substitutions in a germ line antibody are required to initiate significant domain exchange | |
| Robinson et al. | Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4 | |
| Mikell et al. | Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject | |
| Gach et al. | HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study | |
| Chaillon et al. | Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection |